Conquering the final frontier in lung transplantation - Mesenchymal stromal cell therapy for chronic lung allograft dysfunction

点击翻译按钮获取中文摘要

Lung transplantation remains the only treatment option for an increasing number of Australians with end-stage lung disease, however long-term outcomes are severely compromised by the almost universal development of chronic rejection. Mesenchymal stromal cells (MSCs) hold great promise in treating rejection, and in a world-first we have recently demonstrated that this approach is safe. In another world-first, this randomized, controlled study will determine whether MSC therapy is effective.